There is increased investment in gene therapies to treat hemophilia, sickle cell disease and β-thalassemia, however developing these programs pose unique indication-specific challenges. Understanding the specific challenges and opportunities in this space is crucial to ensure the success of your gene therapy program.
This focused agenda brings together key thought leaders across the blood disease space to share their expertise at every stage of clinical and commercial development, including:
- Gene Editing Innovators
- Clinical Developers
- Patient Advocacy Experts
- Commercial Launch Leaders
- Market Access Strategists
Companies confirmed to present their insights into these key topics include: